zerumbone and Colitis

Chronic inflammation has been linked to colitis-associated colorectal cancer in humans. The human symbiont enterotoxigenic Bacteroides fragilis (ETBF), a pro-carcinogenic bacterium, has the potential to initiate and/or promote colorectal cancer. Antibiotic treatment of ETBF has shown promise in decreasing colonic polyp formation in murine models of colon cancer. However, there are no reported natural products that have shown efficacy in decreasing polyp burden. In this study, we investigated the chemopreventive effects of oral administration of zerumbone in ETBF-colonized mice with azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced tumorigenesis. Zerumbone significantly reduced the severity of disease activity index (DAI) scores as well as several parameters of colonic inflammation (i.e., colon weight, colon length, cecum weight and spleen weight). In addition, inflammation of the colon and cecum as well as hyperplasia was reduced. Zerumbone treatment significantly inhibited colonic polyp numbers and prevented macroadenoma progression. Taken together, these findings suggest that oral treatment with zerumbone inhibited ETBF-promoted colon carcinogenesis in mice indicating that zerumbone could be employed as a promising protective agent against ETBF-mediated colorectal cancer.

Topics: Administration, Oral; Animals; Azoxymethane; Bacteroides fragilis; Body Weight; Carcinogenesis; Colitis; Colonic Neoplasms; Dextran Sulfate; Female; Mice; Mice, Inbred BALB C; Protective Agents; Sesquiterpenes; Severity of Illness Index

Topics: Animals; Anti-Bacterial Agents; Bacterial Toxins; Bacteroides fragilis; Bacteroides Infections; Cadherins; Colitis; Colon; Epithelial Cells; HT29 Cells; Humans; Interleukin-17; Interleukin-8; Metalloendopeptidases; Mice; Mice, Inbred C57BL; NF-kappa B; Nitric Oxide Synthase Type II; Sesquiterpenes; Tumor Necrosis Factor-alpha

Ulcerative colitis (UC) and Crohn's disease are inflammatory disorders of unknown cause and difficult to treat, though some synthetic chemicals, including ligands for peroxisome proliferator-activated receptors (PPARs), are anticipated to be useful drugs. In contrast, few food phytochemicals have been reported to suppress colitis in animal models. The present study was undertaken to explore the suppressive efficacy of zerumbone (ZER), a sesquiterpenoid present in the rhizome of Zingiber zerumbet Smith that is used as a condiment in Southeast Asian countries and known to be a potent suppressant of cyclooxygenase (COX)-2 and inducible nitric oxide synthase expression in cell culture systems. Acute colitis was induced by exposing female ICR mice to 5% DSS in drinking water for 1 week. One week prior to DSS administration, the experimental mice were fed ZER alone, nimesulide (NIM, a selective COX-2 inhibitor) alone, or both in combination (1000 ppm each) for a total of 2 weeks. Inflammatory biomarkers, i.e. interleukin (IL)-1alpha and IL-1beta, tumor necrosis factor (TNF)-alpha, and prostaglandin (PG)E(2) and PGF(2alpha) in colonic mucosa were quantified by an enzyme-linked immunosorbent assay in conjunction with histological alterations. Oral feeding of ZER significantly lowered the levels of IL-1beta [inhibitory rate (IR)=34%], TNF-alpha (IR=29%), and PGE(2) (IR=73%) and suppressed DSS-induced colitis, whereas NIM suppressed the histological changes induced by DSS without affecting inflammatory biomarkers. However, their treatment in combination was most effective for suppressing these biomarkers. Our results suggest that ZER is a novel food factor for mitigating experimental UC and that use of a combination of agents, with different modes of actions, may be an effective anti-inflammatory strategy.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Dextran Sulfate; Disease Models, Animal; Drug Therapy, Combination; Female; Mice; Sesquiterpenes; Sulfonamides; Zingiber officinale